FAKnostics has developed a series of hydrocarbon-stapled peptides that block the FAK FAT domain.
Our peptides have demonstrated enhanced alpha helicity, permeability, binding affinity, proteolytic resistance, and pharmacokinetic properties.
Currently, we have several very promising anti-cancer products in in-vitro, pre-clinical, and pre-IND stages.
Multiple companies have developed FAK inhibitors that target the kinase domain of FAK, but most have failed in clinical trials due to innate resistance mechanisms.
FAKnostics' inhibitor targets the non-kinase domain, which plays important roles in cancer progression and metastasis.
Our FAKnosTest® companion diagnostic is based on our proprietary FAK antibody thoroughly tested on thousands of biopsies.
Proof of Concept
FAKnosTest CRC Prognostic
Companion Pancreatic Cancer